NCT06707610 2025-03-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1 Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Neovia Oncology Ltd.
M.D. Anderson Cancer Center
Nektar Therapeutics
Pfizer
M.D. Anderson Cancer Center